science News
Most Popular science Story
Risk averse? Not us, says top FDA official
Is a rising tide of risk aversion at a post-Vioxx FDA behind the agency's anemic approval record? No way, say the FDA's Read more...
Latest Headlines
- June 16, 2008
- March 26, 2008
- January 28, 2008
- January 7, 2008
- October 30, 2007
- October 19, 2007
- January 31, 2007
- October 8, 2006
- August 20, 2006
- July 20, 2006
- April 20, 2006
- January 9, 2006
- December 22, 2005
- December 15, 2005
- October 6, 2005
- July 6, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
